LOS ANGELES - IndianaStop -- By CCHR International

The mental health industry watchdog, Citizens Commission on Human Rights International (CCHR), warns that organized psychiatry's long history of downplaying risks associated with some psychiatric drugs and limiting full disclosure to patients could thwart or weaken the safeguards in the Department of Health and Human Services' May 2026 plan to address overprescribing and support safe deprescribing and tapering of antidepressants. CCHR urges federal officials to move forward with even stronger protections for informed consent and patient safety.

The federal shift toward deprescribing marks a long-overdue health action, aligning with international concerns, such as the 2024 UK All-Party Parliamentary Group report, which called for deprescribing antidepressants and the creation of withdrawal support services.[1]

Yet some within U.S. psychiatry, while appearing to welcome efforts to improve the quality and safety of mental health treatment, minimize legitimate concerns about antidepressants and instead cite workforce shortages and limited beds. CCHR sees this as a thinly veiled request for more funding. This stance persists despite mental health spending skyrocketing 241% from $40.9 billion in 2000 to $139.6 billion in 2021, while outcomes have worsened, as highlighted in an April 2026 U.S. House Subcommittee roundtable.

Following HHS consumer-protection plans, a psychiatric committee formed in 2025 to counter these initiatives and recently conducted a highly selective survey at a major psychiatric annual meeting. Of 229 psychiatrists who responded, 94% disagreed that the HHS reforms would help their field. CCHR sees this as an exercise designed to manufacture opposition to deprescribing in order to protect antidepressant prescribing.

In 2002, a psychiatric leader who now serves as secretary of that committee was president and CEO of a major psychiatric hospital in Maryland, where clinical drug trials were conducted under contracts from multiple pharmaceutical companies, including for "treatment-resistant depression." It was publicly stated that there was tremendous excitement in new psychiatric pharmaceuticals, noting the hospital's large patient volume made it a valuable asset to pharmaceutical clients. A high-profile mass shooter was once treated at this hospital, where he was prescribed antidepressants linked to violent and suicidal behavior.

More on indianastop.com

• Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys
• Sounds of LA County: 27 Parks.108 Concerts. One County
• Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa
• City of Evansville to Power Municipal Facilities with Renewable Energy
• Lakeshore Bone & Joint Institute Expands Access to Same-Day Orthopedic Care in Michigan City

In 2004, the psychiatrist formally opposed an FDA Black Box warning on SSRI antidepressants and suicide risk in children. Together with the president of a U.S. psychiatric association, he issued a joint statement expressing deep concern that a black-box warning might have a chilling effect on prescribing. This was taken at a time when at least 100 families in the U.S. had loved ones who committed suicide while taking antidepressants.

In 1991, CCHR's actions had prompted an FDA public hearing into antidepressants linked to suicide and violence, where testimony from patients and families was ignored by a panel of psychiatrists. In 2004, CCHR again assisted families who testified before another FDA hearing on antidepressants inducing suicide, which contributed to the Black Box suicide warning issued in October that year. The chief communications officer of the main psychiatric body acknowledged CCHR as an opponent due to its well-publicized campaign. He noted: "We understood that we could not just select one person to testify and expect that person to carry the organization's message." The body coordinated with pharmaceutical-funded patient advocacy groups that could be used indirectly to promote antidepressants.

Such warnings potentially threatened a booming industry. Between 1998 and 2002, some two million commercially insured pediatric beneficiaries were taking antidepressants. The fastest-growing segment was preschoolers aged 0-5 years. Today, global sales of antidepressants have reached $15.6 billion.

Jan Eastgate, President of CCHR International, said, "For years, the mental health field touted the mantra that depression was caused by a chemical imbalance—a claim CCHR refuted since the first SSRI antidepressant came on the market in 1988."

Yet, in 2001, patient materials from a psychiatric professional body stated that antidepressants "may be prescribed to correct imbalances in the levels of chemicals in the brain" and are not "habit-forming." In May 2005, CCHR organized a joint letter to the FDA signed by more than 100 doctors, stating that such advertisements were not supported by science and misled patients.

On June 27, 2005, the senior figure representing this new psychiatric committee appeared on NBC's Today Show and called it "total nonsense" to say there was no evidence that drugs correct a chemical imbalance. However, weeks later, he admitted to People magazine that there was no lab test to prove a chemical imbalance causes any mental disorder.

More on indianastop.com

• Stigma Across Borders: Concerns Grow Over Discrimination Against Shincheonji Members Abroad
• World Cup Crowds Are a Stress Test for America's Restrooms
• Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
• How Sacramento Families Are Using Private Autopsies to Protect Inheritances, Resolve Insurance Claims, and Find Closure
• Los Angeles' Best Food: Food Journal Magazine Examines the Trends Shaping the City's Dining Scene

In 2021, psychiatric agency materials still suggested that differences in brain chemicals may contribute to depression symptoms. A major 2022 University College London umbrella review in Molecular Psychiatry delivered irrefutable evidence disproving the serotonin theory of depression.[2]

Psychiatric organizations have also consistently downplayed risks, including potential violence, now widely recognized.[3] Withdrawal risks were similarly minimized. Patients experiencing severe symptoms were often misdiagnosed as relapsing, trapping them in long-term use. The term "antidepressant discontinuation syndrome" emerged from a 1996 pharmaceutical industry-funded meeting to deflect attention from antidepressant dependency and withdrawal.

In 2026, Psychiatric Times admitted these risks had been routinely denied, minimized, or reframed. Withdrawal effects include, brain zaps, cognitive impairment, akathisia, anxiety, irritability, emotional blunting, and impaired concentration.

Eastgate warns: "Given this decades-long pattern of downplaying risks, opposing warnings and maintaining pharmaceutical relationships, claims that organized psychiatry will genuinely support the current Administration's deprescribing efforts lack credibility. Their track record suggests a continued priority on preserving unchecked prescribing patterns over patient safety."

CCHR urges federal officials to fully implement the HHS plan with strong safeguards for informed consent and deprescribing support.

CCHR was founded in 1969 by the Church of Scientology and the late Professor Thomas Szasz, internationally renowned professor of psychiatry, and has helped obtain hundreds of laws that protect mental health patients.

Sources:

[1] Rachel Kelly, "Our mental health crisis won't be solved by pills alone," The New Statesman, 31 May 2024

[2] Mark A. Horowitz, Joanna Moncrieff, et al., "The serotonin theory of depression: a systematic umbrella review of the evidence," Molecular Psychiatry, 20 July 2022

[3] Peter C. Gøtzsche, M.D., "Antidepressants can cause homicide," Substack, 3 June 2026